Degradation of refractory organic matter in MBR effluent from treating landfill leachate by the UV-nZVI-HO system.

In this study, nano zero-valent iron (nZVI) was used as the Fe source in the Fenton reaction, and a UV-nZVI-HO system was constructed to efficiently degrade and mineralize refractory organic matter in landfill leachate. The results showed that under the optimal conditions (initial pH = 3, UV = 14 W, nZVI = 0.5 g/L, and [HO] = 30 mM), the removal efficiencies of total organic carbon, absorbance at 254 nm, and color number were 61.

Degradation of refractory organic matter in MBR effluent from treating landfill leachate by UV/PMS and UV/HO: a comparative study.

This study applied ultraviolet/peroxymonosulfate (UV/PMS) and UV/hydrogen peroxide (UV/HO) processes to the advanced treatment of membrane bioreactor (MBR) effluent. The degradation efficiency of refractory organic matter and the reaction mechanisms of the two processes were systematically investigated. The results showed that the degradation efficiency of the UV/PMS processes was significantly lower than that of the UV/HO process when the PMS concentration was significantly lower than the HO concentration, e.

Recent advance in the development of novel, selective and potent FGFR inhibitors.

Mutation or abnormal expression of protein tyrosine kinases (PTKs) is one of the main causes of cancer. Fibroblast growth factor receptors (FGFRs) are a subfamily of tyrosine kinase receptors, which have four subtypes including FGFR1, FGFR2, FGFR3 and FGFR4. Their abnormal expression in cells is considered to be the main cause of tumorigenesis, so inhibiting FGFRs is thought to be important targets for cancer treatment.

Long noncoding RNA DLX6-AS1 targets miR-124-3p/CDK4 to accelerate Ewing's sarcoma.

Ewing's sarcoma is one of leading cause of malignancy occurred in the children and adolescents worldwide. Given the emerging critical role of long noncoding RNA (lncRNA) in the human cancer, as well as Ewing's sarcoma, we aim to identify the biological role of DLX6-AS1 in the tumorigenesis. Results unveil that DLX6-AS1 expression was increased in the tissue sample and cells.